Year: 2020

BERGENBIO TO PRESENT AT Sachs Annual Biotech in Europe Forum

September 18, 2020

Bergen, Norway, 18 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES

September 1, 2020

Bergen, Norway, 01 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020

August 18, 2020

Bergen, Norway, 18 August 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

August 10, 2020

Bergen, Norway, 10 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

UPDATE ON BEMCENTINIB’S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC

July 28, 2020

BerGenBio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib…

Read More

BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB

July 20, 2020

Bergen, Norway, 20 July 2020 –BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More